Riboxin is an anabolic medicine that has antihypoxic and antiarrhythmic effects. It is a precursor of ATP, is directly involved in glucose metabolism and promotes metabolism activation in the conditions of hypoxia and lack of ATP.
Complex treatment of coronary heart disease (condition after myocardial infarction, angina), arrhythmias, cardiac glycoside overdose. Treatment of cardiomyopathies of different aetiology, myocardiodystrophies (associated with heavy physical activity, of infectious and endocrine aetiology), myocarditis.
Treatment of liver diseases (hepatitis, cirrhosis, fatty liver disease). Prevention of leukopenia during irradiation.
Improving vision in open-angle glaucoma with normalised intraocular pressure.
The medicine is used in adults as intravenous push or drip (slowly) at a rate of 40-60 drops per minute.
The medicine is diluted in 5 % glucose solution or 0.9 % sodium chloride solution (up to 250 ml) for intravenous drip administration. At the beginning of treatment 200 mg (10 ml of 2 % solution) is administered 1 time per day. Subsequently, if well-tolerated, the dose can be increased to 400 mg (20 ml of 2 % solution) 1–2 times per day. The course of treatment is determined on an individual basis, with an average of 10-15 days.
Intravenous push is possible in acute arrhythmias in a single dose of 200–400 mg (10–20 ml of 2 % solution).